{"disease":{"id":"advanced-ovarian-cancer","name":"Advanced ovarian cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"pf-07104091-monotherapy-dose-expansion-ovarian","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07104091 monotherapy dose expansion (ovarian)","generic_name":"pf-07104091-monotherapy-dose-expansion-ovarian","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[insert molecular target]","drug_class":"small molecule","quality_score":35,"revenue":"798","mechanism":""},{"drug_id":"hydroxydaunorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"liposomal-doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03737643","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1407,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04575935","title":"Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06188520","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":564,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01844986","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05867251","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Avenzo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03462212","title":"Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":290,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04180371","title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"BicycleTx Limited","has_results":false},{"nct_id":"NCT01226316","title":"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":285,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03491033","title":"Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06710548","title":"REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06997029","title":"A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04065009","title":"The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06545942","title":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"MOMA Therapeutics","has_results":false},{"nct_id":"NCT04332653","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"NeoImmuneTech","has_results":true},{"nct_id":"NCT07029399","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06236958","title":"Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Luo Chengyan","has_results":false},{"nct_id":"NCT00516724","title":"Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04752826","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT07144826","title":"Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":161,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07514494","title":"Intensification Treatment of Ovarian Cancer by PIPAC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Moscow Regional Oncological Dispensary","has_results":false},{"nct_id":"NCT04360629","title":"Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Jun Zhang","has_results":false},{"nct_id":"NCT04862325","title":"SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT03333915","title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03667716","title":"COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT07059676","title":"Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06055348","title":"SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Biocity Biopharmaceutics Co., Ltd.","has_results":false},{"nct_id":"NCT04354246","title":"COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT03134638","title":"A Study of SY-1365 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":107,"lead_sponsor_name":"Syros Pharmaceuticals","has_results":false},{"nct_id":"NCT07088588","title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":105,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT04556539","title":"Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":104,"lead_sponsor_name":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT06542549","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT05794659","title":"Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Aston Sci. Inc.","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}